Publication at First Faculty of Medicine |
2020
Abstract
The recognition of pathogenetic mechanisms of neuromyelitis optica spectrum disorders (NMOSD) led to the development of new drugs targeting these processes. Those drugs minimize the risk of relapses of the disease.
Instead of original empiric therapeutic procedures, new placebo-controlled double-blinded clinical trials were finished and their results were published. Three new drugs, eculizumab, inebilizumab and satralizumab, with a different mode of action are coming to the market for patients with AQP4-IgGpos NMOSD.
The insight into their mode of action and potential adverse events are essential for their use. The article shows long term management of NMOSD including the symptomatic care.